Details
Stereochemistry | ACHIRAL |
Molecular Formula | C22H28N6O3S.CH4O3S |
Molecular Weight | 552.667 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CS(O)(=O)=O.CC(C)NC1=C(N=CC=C1)N2CCN(CC2)C(=O)C3=CC4=C(N3)C=CC(NS(C)(=O)=O)=C4
InChI
InChIKey=MEPNHSOMXMALDZ-UHFFFAOYSA-N
InChI=1S/C22H28N6O3S.CH4O3S/c1-15(2)24-19-5-4-8-23-21(19)27-9-11-28(12-10-27)22(29)20-14-16-13-17(26-32(3,30)31)6-7-18(16)25-20;1-5(2,3)4/h4-8,13-15,24-26H,9-12H2,1-3H3;1H3,(H,2,3,4)
Molecular Formula | CH4O3S |
Molecular Weight | 96.106 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Molecular Formula | C22H28N6O3S |
Molecular Weight | 456.561 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Delavirdine is a nonnucleoside reverse transcriptase inhibitor (NNRTI). Delavirdine binds directly to reverse transcriptase (RT) and blocks RNA-dependent and DNA-dependent DNA polymerase activities. Delavirdine does not compete with template:primer or deoxynucleoside triphosphates. HIV-2 RT and human cellular DNA polymerases alfa, gamma, or delta are not inhibited by delavirdine. In addition, HIV-1 group O, a group of highly divergent strains that are uncommon in North America, may not be inhibited by delavirdine. Delavirdine is marketed under the trade name Rescriptor, indicated for the treatment of HIV-1 infection in combination with at least 2 other active antiretroviral agents when therapy is warranted. .
Originator
Sources: http://adisinsight.springer.com/drugs/800002084
Curator's Comment: # Pfizer
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
21.0 nM [IC50] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | RESCRIPTOR Approved UseRESCRIPTOR Tablets are indicated for the treatment of HIV-1 infection in combination with at least 2 other active antiretroviral agents when therapy is warranted. The following should be considered before initiating therapy with RESCRIPTOR in treatment-naive patients. There are insufficient data directly comparing antiretroviral regimens containing RESCRIPTOR with currently preferred 3-drug regimens for initial treatment of HIV. In studies comparing regimens consisting of 2 nucleoside reverse transcriptase inhibitors (NRTIs) (currently considered suboptimal) to RESCRIPTOR plus 2 NRTIs, the proportion of patients receiving the regimen containing RESCRIPTOR who achieved and sustained an HIV-1 RNA level <400 copies/mL over 1 year of therapy was relatively low (see DESCRIPTION OF CLINICAL STUDIES). Resistant virus emerges rapidly when RESCRIPTOR is administered as monotherapy. Therefore, RESCRIPTOR should always be administered in combination with other antiretroviral agents. Launch Date8.6011203E11 |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
2.18 μM EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/9164415/ |
200 mg 3 times / day steady-state, oral dose: 200 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
N-DESISOPROPYL DELAVIRDINE plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
2.88 μM EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/9164415/ |
300 mg 3 times / day steady-state, oral dose: 300 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
N-DESISOPROPYL DELAVIRDINE plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
3.23 μM EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/9164415/ |
400 mg 3 times / day steady-state, oral dose: 400 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
N-DESISOPROPYL DELAVIRDINE plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
35 μM |
400 mg 3 times / day steady-state, oral dose: 400 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
DELAVIRDINE plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
|
12.6 μM EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/9164415/ |
200 mg 3 times / day steady-state, oral dose: 200 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
DELAVIRDINE plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
18.8 μM EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/9164415/ |
300 mg 3 times / day steady-state, oral dose: 300 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
DELAVIRDINE plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
26.6 μM EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/9164415/ |
400 mg 3 times / day steady-state, oral dose: 400 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
DELAVIRDINE plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: MALE food status: UNKNOWN |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
180 μM × h |
400 mg 3 times / day steady-state, oral dose: 400 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
DELAVIRDINE plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
4.71 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/9164415/ |
200 mg 3 times / day steady-state, oral dose: 200 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
N-DESISOPROPYL DELAVIRDINE plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
6.18 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/9164415/ |
300 mg 3 times / day steady-state, oral dose: 300 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
N-DESISOPROPYL DELAVIRDINE plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
7.5 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/9164415/ |
400 mg 3 times / day steady-state, oral dose: 400 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
N-DESISOPROPYL DELAVIRDINE plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
5.8 h |
400 mg 3 times / day steady-state, oral dose: 400 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
DELAVIRDINE plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
|
2.59 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/9164415/ |
200 mg 3 times / day steady-state, oral dose: 200 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
DELAVIRDINE plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
3.33 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/9164415/ |
300 mg 3 times / day steady-state, oral dose: 300 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
DELAVIRDINE plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
4.12 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/9164415/ |
400 mg 3 times / day steady-state, oral dose: 400 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
DELAVIRDINE plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: MALE food status: UNKNOWN |
Funbound
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
2% |
400 mg 3 times / day steady-state, oral dose: 400 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
DELAVIRDINE plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
|
2.3% EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/9164415/ |
200 mg 3 times / day steady-state, oral dose: 200 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
DELAVIRDINE plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
2.3% EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/9164415/ |
300 mg 3 times / day steady-state, oral dose: 300 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
DELAVIRDINE plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
2.3% EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/9164415/ |
400 mg 3 times / day steady-state, oral dose: 400 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
DELAVIRDINE plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: MALE food status: UNKNOWN |
Doses
Dose | Population | Adverse events |
---|---|---|
400 mg 3 times / day steady, oral Highest studied dose Dose: 400 mg, 3 times / day Route: oral Route: steady Dose: 400 mg, 3 times / day Sources: |
unhealthy, >18 years n = 30 Health Status: unhealthy Condition: HIV infection Age Group: >18 years Sex: M+F Population Size: 30 Sources: |
Disc. AE: Rash, Oral lesion... Other AEs: Fever, Thrombocytopenia... AEs leading to discontinuation/dose reduction: Rash (grade 3-4, 36%) Other AEs:Oral lesion (1 patient) Function liver abnormal (2 patients) Headache (grade 4, 1 patient) Fever (grade 3, 1 patient) Sources: Thrombocytopenia (1 patient) Nausea (1 patient) Fatigue (1 patient) |
400 mg 3 times / day multiple, oral Highest studied dose Dose: 400 mg, 3 times / day Route: oral Route: multiple Dose: 400 mg, 3 times / day Sources: |
unhealthy n = 412 Health Status: unhealthy Population Size: 412 Sources: |
Disc. AE: Rash... AEs leading to discontinuation/dose reduction: Rash (3.2%) Sources: |
AEs
AE | Significance | Dose | Population |
---|---|---|---|
Fatigue | 1 patient | 400 mg 3 times / day steady, oral Highest studied dose Dose: 400 mg, 3 times / day Route: oral Route: steady Dose: 400 mg, 3 times / day Sources: |
unhealthy, >18 years n = 30 Health Status: unhealthy Condition: HIV infection Age Group: >18 years Sex: M+F Population Size: 30 Sources: |
Nausea | 1 patient | 400 mg 3 times / day steady, oral Highest studied dose Dose: 400 mg, 3 times / day Route: oral Route: steady Dose: 400 mg, 3 times / day Sources: |
unhealthy, >18 years n = 30 Health Status: unhealthy Condition: HIV infection Age Group: >18 years Sex: M+F Population Size: 30 Sources: |
Thrombocytopenia | 1 patient | 400 mg 3 times / day steady, oral Highest studied dose Dose: 400 mg, 3 times / day Route: oral Route: steady Dose: 400 mg, 3 times / day Sources: |
unhealthy, >18 years n = 30 Health Status: unhealthy Condition: HIV infection Age Group: >18 years Sex: M+F Population Size: 30 Sources: |
Oral lesion | 1 patient Disc. AE |
400 mg 3 times / day steady, oral Highest studied dose Dose: 400 mg, 3 times / day Route: oral Route: steady Dose: 400 mg, 3 times / day Sources: |
unhealthy, >18 years n = 30 Health Status: unhealthy Condition: HIV infection Age Group: >18 years Sex: M+F Population Size: 30 Sources: |
Function liver abnormal | 2 patients Disc. AE |
400 mg 3 times / day steady, oral Highest studied dose Dose: 400 mg, 3 times / day Route: oral Route: steady Dose: 400 mg, 3 times / day Sources: |
unhealthy, >18 years n = 30 Health Status: unhealthy Condition: HIV infection Age Group: >18 years Sex: M+F Population Size: 30 Sources: |
Fever | grade 3, 1 patient | 400 mg 3 times / day steady, oral Highest studied dose Dose: 400 mg, 3 times / day Route: oral Route: steady Dose: 400 mg, 3 times / day Sources: |
unhealthy, >18 years n = 30 Health Status: unhealthy Condition: HIV infection Age Group: >18 years Sex: M+F Population Size: 30 Sources: |
Rash | grade 3-4, 36% Disc. AE |
400 mg 3 times / day steady, oral Highest studied dose Dose: 400 mg, 3 times / day Route: oral Route: steady Dose: 400 mg, 3 times / day Sources: |
unhealthy, >18 years n = 30 Health Status: unhealthy Condition: HIV infection Age Group: >18 years Sex: M+F Population Size: 30 Sources: |
Headache | grade 4, 1 patient Disc. AE |
400 mg 3 times / day steady, oral Highest studied dose Dose: 400 mg, 3 times / day Route: oral Route: steady Dose: 400 mg, 3 times / day Sources: |
unhealthy, >18 years n = 30 Health Status: unhealthy Condition: HIV infection Age Group: >18 years Sex: M+F Population Size: 30 Sources: |
Rash | 3.2% Disc. AE |
400 mg 3 times / day multiple, oral Highest studied dose Dose: 400 mg, 3 times / day Route: oral Route: multiple Dose: 400 mg, 3 times / day Sources: |
unhealthy n = 412 Health Status: unhealthy Population Size: 412 Sources: |
Overview
CYP3A4 | CYP2C9 | CYP2D6 | hERG |
---|---|---|---|
OverviewOther
Other Inhibitor | Other Substrate | Other Inducer |
---|---|---|
Drug as perpetrator
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
negligible | ||||
yes [Inhibition 16.7 uM] | ||||
yes [Inhibition 16.7 uM] | ||||
yes [Inhibition 16.7 uM] | ||||
yes [Ki 12.8 uM] | ||||
yes [Ki 2.6 uM] | ||||
yes [Ki 24 uM] | ||||
yes [Ki 9.5 uM] | yes (co-administration study) Comment: coadministration of amprenavir with delavirdine resulted in an approximately 4-fold increase in amprenavir AUC to infinity (AUC∞) and a 6-fold increase in amprenavir Cmin Page: 3.0 |
|||
Sources: https://pubmed.ncbi.nlm.nih.gov/12180537/ |
yes | |||
Sources: https://aac.asm.org/content/48/4/1073 |
yes |
Drug as victim
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
Page: 3.0 |
likely | |||
Sources: https://aac.asm.org/content/48/4/1073 |
no | |||
Page: 3.0 |
yes | yes (co-administration study) Comment: Coadministration of RESCRIPTOR and drugs that induce CYP3A, such as rifampin, may decrease delavirdine plasma concentrations and reduce its therapeutic effect. With rifampin: 97% decrease in AUC Page: 3.0 |
PubMed
Title | Date | PubMed |
---|---|---|
Clinical pharmacokinetics of non-nucleoside reverse transcriptase inhibitors. | 2001 |
|
[Therapeutic aspects of HIV/AIDS infected patients and evaluation of therapeutic protocols]. | 2001 Dec |
|
Synthesis and anti-HIV-1 activity of new delavirdine analogues carrying arylpyrrole moieties. | 2001 Nov |
|
Anti-human immunodeficiency virus drugs are ineffective against Pneumocystis carinii in vitro and in vivo. | 2001 Nov 15 |
|
Drugs for HIV infection. | 2001 Nov 26 |
|
Can delavirdine substitute for ritonavir? | 2001 Nov-Dec |
|
Baseline antiretroviral drug susceptibility influences treatment response in patients receiving saquinavir-enhancing therapy. | 2001 Nov-Dec |
|
HIV-protease inhibitors alter retinoic acid synthesis. | 2001 Oct 19 |
|
Interactions between antiretroviral drugs and drugs used for the therapy of the metabolic complications encountered during HIV infection. | 2002 |
|
Lack of hepatotoxicity associated with nonnucleoside reverse transcriptase inhibitors. | 2002 Apr 1 |
|
Rhabdomyolysis with acute renal failure probably related to the interaction of atorvastatin and delavirdine. | 2002 Apr 15 |
|
Genotypic and phenotypic resistance patterns in early-stage HIV-1-infected patients failing initial therapy with stavudine, didanosine and nevirapine. | 2002 Dec |
|
Pharmacokinetic interaction between amprenavir and delavirdine: evidence of induced clearance by amprenavir. | 2002 Dec |
|
Structural requirements for potent anti-human immunodeficiency virus (HIV) and sperm-immobilizing activities of cyclohexenyl thiourea and urea non-nucleoside inhibitors of HIV-1 reverse transcriptase. | 2002 Dec |
|
Synthesis of novel N-1 (allyloxymethyl) analogues of 6-benzyl-1-(ethoxymethyl)-5-isopropyluracil (MKC-442, emivirine) with improved activity against HIV-1 and its mutants. | 2002 Dec 19 |
|
Differential modulation of P-glycoprotein expression and activity by non-nucleoside HIV-1 reverse transcriptase inhibitors in cell culture. | 2002 Jul |
|
Genetic divergence of human immunodeficiency virus type 1 Ethiopian clade C reverse transcriptase (RT) and rapid development of resistance against nonnucleoside inhibitors of RT. | 2002 Jul |
|
New developments in anti-HIV chemotherapy. | 2002 Jul 18 |
|
Simple and rapid quantification of the non-nucleoside reverse transcriptase inhibitors nevirapine, delavirdine, and efavirenz in human blood plasma using high-performance liquid chromatography with ultraviolet absorbance detection. | 2002 Jul 5 |
|
Nelfinavir urinary stones. | 2002 Mar |
|
Rifampin and rifabutin drug interactions: an update. | 2002 May 13 |
|
Delavirdine in rescue regimens. | 2002 May-Jun |
|
New anti-HIV agents and targets. | 2002 Nov |
|
Polymorphisms of cytotoxic T-lymphocyte (CTL) and T-helper epitopes within reverse transcriptase (RT) of HIV-1 subtype C from Ethiopia and Botswana following selection of antiretroviral drug resistance. | 2002 Nov |
|
Hypersusceptibility to non-nucleoside reverse transcriptase inhibitors in HIV-1: clinical, phenotypic and genotypic correlates. | 2002 Oct 18 |
|
Durability of response to treatment among antiretroviral-experienced subjects: 48-week results from AIDS Clinical Trials Group Protocol 359. | 2002 Sep 1 |
|
Effect of delavirdine on plasma lipids and lipoproteins in patients receiving antiretroviral therapy. | 2002 Sep 6 |
|
Pharmacia pilots patent share for HIV drug. | 2003 Apr |
|
3-iodo-4-phenoxypyridinones (IOPY's), a new family of highly potent non-nucleoside inhibitors of HIV-1 reverse transcriptase. | 2003 Dec 15 |
|
Provider bias in the selection of non-nucleoside reverse transcriptase inhibitor and protease inhibitor-based highly active antiretroviral therapy and HIV treatment outcomes in observational studies. | 2003 Dec 5 |
|
Delavirdine malabsorption in HIV-infected subjects with spontaneous gastric hypoacidity. | 2003 Feb |
|
Simultaneous determination of nine antiretroviral compounds in human plasma using liquid chromatography. | 2003 Feb 5 |
|
Pharmacokinetic interaction between amprenavir and delavirdine after multiple-dose administration in healthy volunteers. | 2003 Jan |
|
Amino acid substitutions at position 190 of human immunodeficiency virus type 1 reverse transcriptase increase susceptibility to delavirdine and impair virus replication. | 2003 Jan |
|
A V106M mutation in HIV-1 clade C viruses exposed to efavirenz confers cross-resistance to non-nucleoside reverse transcriptase inhibitors. | 2003 Jan 3 |
|
Use of HIV-1 reverse transcriptase recovered from human plasma for phenotypic drug susceptibility testing. | 2003 Jul 4 |
|
Comparison of nine resistance interpretation systems for HIV-1 genotyping. | 2003 Jun |
|
Protease inhibitor-sparing regimens: new evidence strengthens position. | 2003 Jun 1 |
|
Hypersusceptibility to non-nucleoside reverse transcriptase inhibitors in HIV-1. | 2003 Jun 13 |
|
Toxicity of non-nucleoside analogue reverse transcriptase inhibitors. | 2003 May |
|
Effects of imatinib mesylate (STI571, Glivec) on the pharmacokinetics of simvastatin, a cytochrome p450 3A4 substrate, in patients with chronic myeloid leukaemia. | 2003 Nov 17 |
|
Modest decreases in NNRTI susceptibility do not influence virological outcome in patients receiving initial NNRTI-containing triple therapy. | 2003 Oct |
|
Identification and prediction of promiscuous aggregating inhibitors among known drugs. | 2003 Oct 9 |
|
Pfizer announces free drug program. | 2003 Sep |
|
Drug resistance profiles of recombinant reverse transcriptases from human immunodeficiency virus type 1 subtypes A/E, B, and C. | 2003 Sep |
|
Sex-based differences in saquinavir pharmacology and virologic response in AIDS Clinical Trials Group Study 359. | 2004 Apr 1 |
|
Susceptibility of HIV-2, SIV and SHIV to various anti-HIV-1 compounds: implications for treatment and postexposure prophylaxis. | 2004 Feb |
|
Novel benzophenones as non-nucleoside reverse transcriptase inhibitors of HIV-1. | 2004 Feb 26 |
|
Clinical efficacy of antiretroviral combination therapy based on protease inhibitors or non-nucleoside analogue reverse transcriptase inhibitors: indirect comparison of controlled trials. | 2004 Jan 31 |
|
Roles of conformational and positional adaptability in structure-based design of TMC125-R165335 (etravirine) and related non-nucleoside reverse transcriptase inhibitors that are highly potent and effective against wild-type and drug-resistant HIV-1 variants. | 2004 May 6 |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: https://www.drugs.com/ppa/delavirdine.html
HIV-1 infection (part of combination): Oral: 400 mg 3 times/day
Route of Administration:
Oral
In vitro anti-HIV-1 activity of delavirdine was assessed by infecting cell lines of lymphoblastic and monocytic origin and peripheral blood lymphocytes
with laboratory and clinical isolates of HIV-1. IC50 and IC90 values (50% and 90% inhibitory concentrations) for laboratory isolates (n = 5) ranged from 0.005 to 0.030 uM and 0.04 to 0.10 uM, respectively. Mean IC50 of clinical isolates (n = 74) was 0.038 uM (range: 0.001 to 40 0.69 uM); 73 of 74 clinical isolates had an IC50 =0.18 uM. The IC90 of 24 of these clinical isolates ranged from 0.05 to 0.10 uM.
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 16 17:20:11 UTC 2022
by
admin
on
Fri Dec 16 17:20:11 UTC 2022
|
Record UNII |
421105KRQE
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C97453
Created by
admin on Fri Dec 16 17:20:11 UTC 2022 , Edited by admin on Fri Dec 16 17:20:11 UTC 2022
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
7162
Created by
admin on Fri Dec 16 17:20:11 UTC 2022 , Edited by admin on Fri Dec 16 17:20:11 UTC 2022
|
PRIMARY | |||
|
4379
Created by
admin on Fri Dec 16 17:20:11 UTC 2022 , Edited by admin on Fri Dec 16 17:20:11 UTC 2022
|
PRIMARY | |||
|
SUB01575MIG
Created by
admin on Fri Dec 16 17:20:11 UTC 2022 , Edited by admin on Fri Dec 16 17:20:11 UTC 2022
|
PRIMARY | |||
|
441386
Created by
admin on Fri Dec 16 17:20:11 UTC 2022 , Edited by admin on Fri Dec 16 17:20:11 UTC 2022
|
PRIMARY | |||
|
DBSALT000038
Created by
admin on Fri Dec 16 17:20:11 UTC 2022 , Edited by admin on Fri Dec 16 17:20:11 UTC 2022
|
PRIMARY | |||
|
421105KRQE
Created by
admin on Fri Dec 16 17:20:11 UTC 2022 , Edited by admin on Fri Dec 16 17:20:11 UTC 2022
|
PRIMARY | |||
|
147221-93-0
Created by
admin on Fri Dec 16 17:20:11 UTC 2022 , Edited by admin on Fri Dec 16 17:20:11 UTC 2022
|
PRIMARY | |||
|
421105KRQE
Created by
admin on Fri Dec 16 17:20:11 UTC 2022 , Edited by admin on Fri Dec 16 17:20:11 UTC 2022
|
PRIMARY | |||
|
DTXSID701017136
Created by
admin on Fri Dec 16 17:20:11 UTC 2022 , Edited by admin on Fri Dec 16 17:20:11 UTC 2022
|
PRIMARY | |||
|
M4152
Created by
admin on Fri Dec 16 17:20:11 UTC 2022 , Edited by admin on Fri Dec 16 17:20:11 UTC 2022
|
PRIMARY | Merck Index | ||
|
C28974
Created by
admin on Fri Dec 16 17:20:11 UTC 2022 , Edited by admin on Fri Dec 16 17:20:11 UTC 2022
|
PRIMARY | |||
|
142152
Created by
admin on Fri Dec 16 17:20:11 UTC 2022 , Edited by admin on Fri Dec 16 17:20:11 UTC 2022
|
PRIMARY | RxNorm | ||
|
CHEMBL593
Created by
admin on Fri Dec 16 17:20:11 UTC 2022 , Edited by admin on Fri Dec 16 17:20:11 UTC 2022
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
PARENT -> SALT/SOLVATE | |||
|
PARENT -> SALT/SOLVATE |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |